Why Contamination Risk Should Be Discussed Before OEM Tissue Culture Production

OEM tissue culture should begin with system reality, not only quantity and price

An OEM tissue culture project should not begin only with “how much, how many and when?” It should begin with an assessment of plant readiness, mother-plant quality, contamination risk, multiplication cycles and delivery criteria. The USDA/ARS Micropropagation system document reinforces that micropropagation is a production system to be designed, not a number request that automatically becomes finished output.

When customers understand that the process has multiple stages, planning becomes more realistic: explant initiation, shoot multiplication, rooting and acclimatization. Each stage has checkpoints and risks that should be discussed before production begins.

Discussing risk is not a way to create fear

Risk topics should include whether mother plants may carry latent contaminants, whether the plant is difficult to initiate, whether browning is likely, how quickly it multiplies, how easily it roots and what rejection criteria should apply. Cassells (2012), in a chapter on pathogen and biological contamination management, supports the view that biological risk management is part of plant tissue culture itself, not a topic to raise only after a problem appears.

Discussing risk early does not weaken the laboratory's credibility. It creates mature business expectations. Customers can see that the laboratory is not selling attractive promises. It is helping plan production according to plant biology.

Academic sources improve the customer conversation

Cassells (2001) focuses on the impact of contamination in tissue culture, while Herman (2017) presents contamination as both a challenge and an opportunity for better detection and control. When these sources are used in customer communication, risk is no longer positioned as an excuse. It becomes a documented reality of biological production.

For OEM projects, this changes the conversation from “why can't it be faster and complete?” to “how should we start in order to reduce risk responsibly?” This is where the laboratory becomes more than a production vendor. It becomes a production-planning partner.

What should be agreed before work begins

Before production starts, both sides should agree on mother-plant source, initiation volume, target quantity, delivery stage, reporting method, progress-review timing and decision rules if high contamination, slow response or weak rooting appears. These agreements reduce ambiguity and give both sides a shared decision language.

The goal of good OEM production is not always the fastest possible path. It is the fastest path that still respects quality and plant readiness for downstream use, whether that means nursery handling, field planting or a commercial sales plan.

If you are planning commercial plant production, OEM propagation or tissue-culture-based plant multiplication, Thai Tissue Culture International can help evaluate plant readiness, plan risk and design a production process that communicates clearly from the first day.

References

- USDA Agricultural Research Service. (1999). Micropropagation system. In Vitro Cellular & Developmental Biology - Plant, 35, 275-284. https://www.ars.usda.gov/ARSUserFiles/4630/InVitro/10.%20In%20Vitro%20-%20Plant%2035%20275-284%20%281999%29%20Microprop%20system.pdf

- Cassells, A. C. (2012). Pathogen and biological contamination management in plant tissue culture: phytopathogens, vitro pathogens, and vitro pests. Methods in Molecular Biology, 877. https://pubmed.ncbi.nlm.nih.gov/22610620/

- Herman, E. B. (2017). Plant tissue culture contamination: challenges and opportunities. Acta Horticulturae, 1155, 231-238. https://www.ishs.org/ishs-article/1155_33/

- Cassells, A. C. (2001). Contamination and its impact in tissue culture. Acta Horticulturae, 560, 353-359. https://www.ishs.org/ishs-article/560_66